Inclusion Criteria:

• Women age 18 years or older.
• Able to provide a written informed consent and who understand and agree to all study procedures required.
• A newly diagnosed adnexal mass was confirmed by imaging (computed tomography, ultrasonography, or magnetic resonance imaging) prior to enrollment.
  • Planned diagnostic procedure or surgery by the subject’s physician to remove the adnexal masses. This may occur within 90 days or greater of imaging (Note that study participants must undergo a procedure allowing tissue-based diagnosis (e.g., open or laparoscopic, biopsy, ascites aspiration, fine needle aspirate, or surgical removal or debulking of the adnexal mass) prior to initiation of any local or systemic antineoplastic therapy); or
  • Women with newly diagnosed clinically benign adnexal mass(es) for whom surgery is not planned as determined by the treating physician.

Exclusion Criteria:

• Had/Has a diagnosis of invasive malignancy (exception: non-melanoma skin cancers) in the previous 5 years.
• Currently receiving or ever received any of the following prior cancer therapies in the previous 5 years: curative surgical resection, local or systemic chemotherapy, targeted therapy, immunotherapy including cancer vaccines, hormone therapy, or radiation therapy.
• Pregnancy (by self-report of pregnancy status).
• Current febrile illness.
• Acute exacerbation or flare of an inflammatory condition requiring escalation in therapy.
• Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant.
• Poor health status or unfit to tolerate blood draw.

Eligibility last updated 4/14/22. Questions regarding updates should be directed to the study team contact.